MarketCap
Facebook
X
Telegram
scPharmaceuticals ROCE Ratio | SCPH
Annual ROCE Ratio scPharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -486.31 | -148.84 | -49.92 | -45.73 | -30.01 | -45.67 | -34.07 | -20.33 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.33 | -486.31 | -107.61 |
Quarterly ROCE Ratio scPharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 198.3 | 66.7 | -279.65 | -309.84 | -272.42 | -131.65 | -67.11 | -99.24 | -92.33 | -85.31 | -70.07 | -79.43 | -56.65 | -42.29 | -27.63 | -37.9 | -37.89 | -36.63 | -27.7 | -39.95 | -43.96 | -51.84 | -43.75 | -51.17 | -51.5 | -48.27 | -31.04 | -36.0 | -34.73 | -26.83 | -15.78 | -4.95 | -6.15 | -4.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 198.3 | -309.84 | -58.22 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Johnson & Johnson
JNJ
|
14.23 | $ 281.13 | -0.35 % | $ 677 B |  USA |
 |
Kala Pharmaceuticals
KALA
|
-559.76 | $ 0.17 | -2.59 % | $ 1.39 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-167.62 | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
322.88 | - | 3.77 % | $ 22.4 M | USA |
 |
Global Blood Therapeutics
GBT
|
-146.47 | - | - | $ 4.62 B | USA |
 |
Longeveron
LGVN
|
-377.18 | $ 2.77 | 37.81 % | $ 48.7 B | USA |
 |
Inozyme Pharma
INZY
|
-179.9 | - | - | $ 207 M | USA |
 |
MediWound Ltd.
MDWD
|
-38.77 | $ 14.05 | -0.21 % | $ 382 M |  Israel |
 |
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-3.47 | $ 94.4 | 1.31 % | $ 4.74 B | USA |
 |
NanoString Technologies
NSTG
|
-332.18 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
146.06 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
2710.64 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-66.24 | - | - | $ 59.7 M | USA |
 |
Sierra Oncology
SRRA
|
-98.53 | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-120.22 | $ 1.03 | -6.33 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-65.67 | $ 4.24 | -3.97 % | $ 346 M | USA |
 |
Nektar Therapeutics
NKTR
|
-155.96 | $ 37.82 | -0.01 % | $ 638 M | USA |
 |
Vaccinex
VCNX
|
753.01 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
63.22 | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-82.2 | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
-28.53 | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B |  Britain |
 |
Corner Growth Acquisition Corp.
COOL
|
669.98 | - | -0.89 % | $ 114 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 7.0 | -8.62 % | $ 471 B | Britain |
 |
Mersana Therapeutics
MRSN
|
-36.18 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
31.74 | $ 54.08 | -3.08 % | $ 3.5 B |  Danmark |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-367.47 | - | - | $ 717 K | USA |
 |
Immuron Limited
IMRN
|
-65.47 | $ 0.9 | 2.27 % | $ 208 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-111.7 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
-5.86 | - | - | $ 621 M | Britain |
 |
BioVie
BIVI
|
-216.67 | $ 1.25 | -3.85 % | $ 9.06 M | USA |
 |
Kinnate Biopharma
KNTE
|
-76.05 | - | - | $ 123 M | USA |
 |
Mustang Bio
MBIO
|
-25.13 | $ 0.44 | 12.95 % | $ 2.16 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-66.38 | - | - | $ 7.29 B | USA |
 |
NexImmune
NEXI
|
-939.5 | - | 70.13 % | $ 4.12 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.0 | -9.91 % | $ 87.1 M | USA |
 |
Theravance Biopharma
TBPH
|
6.74 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.06 | -3.72 % | $ 192 M | Israel |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Sanofi
SNY
|
6.44 | $ 48.23 | 0.22 % | $ 58.9 B |  France |
 |
Karuna Therapeutics
KRTX
|
-39.45 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-79.36 | - | - | $ 756 M | USA |